Vaduganathan M, et al. - This study attempted to calculate residual life span and potential survival gains with intensive compared with standard BP control in the SPRINT trial using validated nonparametric age-based methods. Researchers performed a secondary analysis of data from an open-label randomized clinical trial from 102 enrolling clinical sites in the United States. Researchers recruited a sum of 9,361 adults (mean [SD] age at randomization, 68 [9] years; 6029 [64.4%] were men; 5399 [57.7%] were non-Hispanic white individuals). Between November 2010 and March 2013, this analysis included adults who were 50 years or older, were at high cardiovascular risk but without diabetes, and had a screening systolic BP between 130 and 180 mm Hg. Data analysis occurred from May 2019 to December 2019. Among middle-aged and older adults, intensive BP control gains projected survival by 6 months to 3 years at high cardiovascular risk but without diabetes mellitus. These post hoc actuarial analyses from SPRINT support the survival advantages of intensive BP control, particularly among middle-aged adults at risk.